FTC Settles With DermaTend, DERMAdoctor Firms For Unsupported Claims
This article was originally published in The Rose Sheet
Executive Summary
FTC continues to crack down on ads featuring slimming and weight-loss claims without proper substantiation, as well as overreaching skin-care claims, reaching settlements in December with marketers of DermaTend and DERMAdoctor products in two separate cases.
You may also be interested in...
FDA Warns Pharmagel, Updates Webpage On Drug-Claim Violations
Pharmagel's name and billing as "pharmaceutical grade anti-aging skin care" may have drawn FDA's attention, but benefits cited in the agency's warning letter – including collagen- and elastic-building claims – are consistent with FDA's enforcement action against other companies so far in 2015.
Audio Feature: FDA Monitoring Cosmetic Claims, But Litigation Remains Biggest Threat
Attorney Steven Shapiro, a partner at Ullman, Shapiro & Ullman, LLP, offers perspective on what he considers some of the biggest challenges cosmetics companies face in the current regulatory and legal landscape, specifically when it comes to crafting claims. Story features audio clips from the attorney’s interview with “The Rose Sheet.”
FTC Prioritizes Health Claims, Disclosures Enforcement In Coming Year
In a presentation at the National Advertising Division Annual Conference, FTC Chairwoman Edith Ramirez discussed the commission’s priorities for the year ahead. Health claims and inadequate disclosures top the list following related settlements with advertisers in 2013 and the agency’s Operation Full Disclosure initiative.